Why it Matters

The House Ways and Means Health Subcommittee is set to hold a kidney health hearing on March 18, titled "Improving Kidney Health through Better Prevention and Innovative Treatment." The session, chaired by Rep. Vern Buchanan (R-FL), comes as the subcommittee sharpens its focus on chronic disease prevention — and as a sprawling ecosystem of dialysis companies, patient advocates, and pharmaceutical firms continues pouring money into lobbying and campaign contributions aimed squarely at the members who will run the hearing.

Rep. Buchanan has spent the weeks leading up to the hearing laying rhetorical groundwork around chronic disease prevention and nutrition — themes that map directly onto kidney disease prevention policy.

On March 5, Buchanan tweeted that "chronic disease is one of the greatest challenges facing our nation; the solution starts with nutrition." The same day, he posted that "nutrition and prevention are key to tackling chronic disease," crediting HHS Secretary Kennedy for "highlighting my efforts in Congress."

Earlier, on February 18, Buchanan cited a constituent poll showing "92 percent of my constituents support reducing ultra-processed foods and promoting healthier nutrition," adding that "prevention must come first."

None of Buchanan's public communications in the 30-day window before the hearing mentioned kidney disease specifically. But the subcommittee's stated framing — prevention plus innovative treatment — fits neatly into the broader chronic disease agenda he has been building.

The Congressional Kidney Hearing Arrives Amid Active Legislating

While the hearing record lists no bills, at least two pieces of kidney treatment legislation introduced in the 119th Congress could serve as focal points:

Two other measures provide additional context: H.R. 6241, the Urban and Rural Diabetes Initiative Act (diabetes is the leading cause of kidney disease), and H.Res. 416, designating National Hypertension Awareness Month (hypertension is the second leading cause). All remain in introduced status, suggesting the hearing may serve as a vehicle to build momentum.

The hearing's pre-hearing summary states it "may lay the groundwork for future legislative initiatives aimed at improving kidney care, potentially impacting millions of Americans affected by kidney disease."

Lobbying

The lobbying infrastructure behind kidney policy is a well-funded machine. Searches of disclosure filings over the past four quarters returned more than 1,300 filings touching on kidney, dialysis, renal, nephrology, and organ transplant topics.

The two largest dialysis providers in the country — DaVita Inc. and Fresenius Medical Care — each reported spending over $1 million per quarter on lobbying. They are joined by a dense network of advocacy groups, trade associations, and pharmaceutical companies filing disclosures every quarter:

At least 24 distinct kidney-related client organizations are registered as active lobbying clients — representing a broad and well-funded ecosystem that has maintained consistent quarterly engagement with Congress.

3 Follow the Money

The lobbying activity is complemented by targeted PAC contributions from industry players to the very members with jurisdiction over Medicare kidney policy.

Rep. Jason Smith (R-MO), chairman of the full Ways and Means Committee, received contributions from three separate kidney health PACs: $5,000 from DaVita's PAC (DAPAC), $5,000 from the Kidney Care Partners PAC, and $1,500 from the Renal Physicians Association PAC — totaling at least $11,500 in identified contributions.

DaVita's PAC alone has made more than 1,290 contributions across multiple election cycles. Fresenius Medical Care's PAC has logged 279 contributions. The Kidney Care Partners PAC, though smaller with 60 total contributions, tends to give at the $5,000 maximum level.

Rep. Darin LaHood (R-IL), a Ways and Means member, received $2,500 from DaVita's PAC and $5,000 from Fresenius's PAC. Rep. Yvette Clarke (D-NY) received contributions from three kidney PACs totaling at least $12,500.

Ten of the 13 major kidney lobbying organizations identified do not operate PACs, meaning their influence runs entirely through direct lobbying rather than campaign contributions. These include the National Kidney Foundation, American Society of Nephrology, and Dialysis Patient Citizens.

The Broader Context: Medicare, Medicaid, and a Divided Committee

The hearing takes place against a backdrop of broader healthcare fights on the committee. The subcommittee held a hearing on healthcare workforce shortages in late February — a topic directly relevant to kidney treatment capacity.

Democratic members have been sounding alarms about healthcare funding. Rep. Richard Neal (D-MA) warned about "the dangers of Republican cuts to Medicaid and Medicare," while Rep. Dwight Evans (D-PA) said recent budget actions are "already hitting our health care system."

Medicare is the primary payer for end-stage renal disease treatment in the United States, making the Ways and Means Committee's jurisdiction over the program central to any kidney treatment legislation that could emerge from this congressional kidney hearing.

Rep. Greg Murphy (R-NC), a practicing physician on the subcommittee, spoke to the Medical Alley Network in early March about "the future of American health care" and innovative treatment — themes that align with the hearing's stated focus.

What to Watch

The hearing has no confirmed witness list yet, but the landscape suggests several dynamics to track:

  • Whether specific bills get elevated. H.R. 1518 and H.R. 6214 are the most obvious candidates for discussion, given their alignment with the hearing's prevention-and-innovation framing.
  • Industry testimony. With DaVita and Fresenius each spending over $1 million per quarter on lobbying, their perspectives on Medicare payment models and home dialysis expansion are likely to surface.
  • The prevention angle. Buchanan's sustained messaging on nutrition and chronic disease prevention suggests the hearing could push beyond traditional dialysis reimbursement debates toward upstream interventions.
  • Partisan fault lines. Democratic concerns about Medicare and Medicaid funding could shape how the minority engages with any legislative proposals that emerge.

Access the Legis1 platform for comprehensive political news, data, and insights.